STAT Plus: Former Axovant CEO David Hung is back — leading a cancer biotech with hefty funding By KATE SHERIDAN

STAT Plus: Former Axovant CEO David Hung is back — leading a cancer biotech with hefty funding

By KATE SHERIDAN

PHOTO ILLUSTRATION: STAT, PHOTO: HANDOUT

Hung is best known for founding Medivation — which developed Xtandi, a drug for prostate cancer — and then selling the company to Pfizer for $14 billion.

READ MORE